Leila Goudarzimehr
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Leila Goudarzimehr has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Ali Heidari
Student Research Committee, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
1 shared publication - Arshid Yousefi Avarvand
Department of Laboratory Sciences, School of Allied Medical Sciences, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
1 shared publication - Danyal Yarahmadi
Student Research Committee, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
1 shared publication Ebrahim Babadi
Thalassemia & Hemoglobinopathy Research Center Health Research Institute, Ahvaz Jundishapur University of Medical Sciences Ahvaz Iran
1 shared publication- Fatemeh Naseri Rad
School of Medicine, Iran University of Medical Sciences, Tehran, Iran
1 shared publication - Mahdi Amraei
Social Determinants of Health Research center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
1 shared publication
Latest Publications
- Open Access
- 4 July 2026
- Published by Springer Nature in International Journal of Emergency Medicine
- Vol. 19 (1)
Safety and efficacy of chest tube clamping versus non-clamping prior to removal: a systematic review and meta-analysis
Managing chest tubes before removal remains a controversial clinical issue. Clamping a chest tube before removal is a common practice and is often used to assess latent air leaks. We systematically searched MEDLINE/PubMed, Embase, Scopus, and Web of Science from inception to 11 February 2026 for studies comparing clamping versus no clamping before chest-tube removal. Two reviewers independently screened and extracted data. Random effect meta-analyses used REML with Hartung-Knapp adjustment, pooling risk ratios for pneumothorax and re-intervention, and mean differences (days) for hospital length of stay. The results of this study show no significant differences between the clamping vs. no-clamping in terms of pneumothorax/hemothorax recurrence, re-intervention rates, or hospital length of stay. Within different causes of applying chest tube/ chest drain, routine clamping before chest-tube removal did not reduce early recurrence or the need for re-intervention.
- 4 July 2026
- Published by Springer Nature in International Journal of Emergency Medicine
- Vol. 19 (1)
Open AccessSafety and efficacy of chest tube clamping versus non-clamping prior to removal: a systematic review and meta-analysis
Managing chest tubes before removal remains a controversial clinical issue. Clamping a chest tube before removal is a common practice and is often used to assess latent air leaks. We systematically searched MEDLINE/PubMed, Embase, Scopus, and Web of Science from inception to 11 February 2026 for studies comparing clamping versus no clamping before chest-tube removal. Two reviewers independently screened and extracted data. Random effect meta-analyses used REML with Hartung-Knapp adjustment, pooling risk ratios for pneumothorax and re-intervention, and mean differences (days) for hospital length of stay. The results of this study show no significant differences between the clamping vs. no-clamping in terms of pneumothorax/hemothorax recurrence, re-intervention rates, or hospital length of stay. Within different causes of applying chest tube/ chest drain, routine clamping before chest-tube removal did not reduce early recurrence or the need for re-intervention.
- Open Access
- 13 September 2025
- Published by Wiley in Cancer Reports
- Vol. 8 (9) , e70351
Update Prognostic Potency of Vascular Endothelial Growth Factor‐A in the Acute Lymphoblastic Leukemia Landscape: A Meta‐Analysis
Background: Vascular endothelial growth factor‐A (VEGF‐A), In combination with other pro‐angiogenic factors, plays a pivotal role in angiogenesis and the pathogenesis of acute lymphoblastic leukemia (ALL).Aims: This meta‐analysis aims to evaluate the diagnostic value of VEGF‐A and its prognostic relevance in the outcome of patients with ALL.Methods and Results: A comprehensive literature search was conducted up to January 2025 across multiple databases. Standardized mean differences (SMDs) with 95% confidence intervals (CIs) were pooled using a random‐effects model to quantify effect sizes. Subgroup analyses and meta‐regression were employed to explore heterogeneity sources. Data extracted from 15 studies encompassing 674 patients with ALL demonstrated a significant correlation between elevated VEGF‐A levels and unfavorable prognosis (SMD: 0.878; 95% CI: 0.276–1.479; p = 0.004). Notably, increased VEGF‐A levels were particularly evident in pediatric patients older than 8 years (SMD: 0.758; 95% CI: 0.178–1.338; p = 0.010).Conclusion: The results indicate that heightened VEGF‐A expression is associated with poorer clinical outcomes in ALL, supporting its utility as a diagnostic and prognostic biomarker in this patient population.
- 13 September 2025
- Published by Wiley in Cancer Reports
- Vol. 8 (9) , e70351
Open AccessUpdate Prognostic Potency of Vascular Endothelial Growth Factor‐A in the Acute Lymphoblastic Leukemia Landscape: A Meta‐Analysis
Background: Vascular endothelial growth factor‐A (VEGF‐A), In combination with other pro‐angiogenic factors, plays a pivotal role in angiogenesis and the pathogenesis of acute lymphoblastic leukemia (ALL).Aims: This meta‐analysis aims to evaluate the diagnostic value of VEGF‐A and its prognostic relevance in the outcome of patients with ALL.Methods and Results: A comprehensive literature search was conducted up to January 2025 across multiple databases. Standardized mean differences (SMDs) with 95% confidence intervals (CIs) were pooled using a random‐effects model to quantify effect sizes. Subgroup analyses and meta‐regression were employed to explore heterogeneity sources. Data extracted from 15 studies encompassing 674 patients with ALL demonstrated a significant correlation between elevated VEGF‐A levels and unfavorable prognosis (SMD: 0.878; 95% CI: 0.276–1.479; p = 0.004). Notably, increased VEGF‐A levels were particularly evident in pediatric patients older than 8 years (SMD: 0.758; 95% CI: 0.178–1.338; p = 0.010).Conclusion: The results indicate that heightened VEGF‐A expression is associated with poorer clinical outcomes in ALL, supporting its utility as a diagnostic and prognostic biomarker in this patient population.